Navigation Links
Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
Date:6/4/2010

WOODCLIFF LAKE, N.J., June 4 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced the resignation of Lawrence A. Kenyon, executive vice president and chief financial officer, effective June 30, 2010, to pursue other opportunities.  Michael A. Tropiano, Par's Treasurer, will replace Mr. Kenyon.

Mr. Tropiano, 52, joined Par in August 2005 as Vice President and Treasurer.  During his tenure, Mr. Tropiano has led several initiatives including building a Financial, Planning and Analysis team, developing the Company's three-year strategic plan, as well the early redemption of the Company's convertible debentures.  Prior to joining Par, Mr. Tropiano served as Vice President and Corporate Treasurer of MedPointe Pharmaceuticals from 2001-2005 and Assistant Treasurer at Carter–Wallace, Inc. from 1984-2001.  He began his career as a treasury analyst at Orange and Rockland Utilities.  Mr. Tropiano received his Masters of Business Administration in Finance from Fordham University and a Bachelors of Arts in Economics from Siena College.  He is also a Chartered Financial Consultant.

About Par Pharmaceutical

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.  For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such  forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
2. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
3. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
4. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
5. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
6. Jazz Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
7. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
8. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
9. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
10. Thomson CompuMark Launches Worlds Most Comprehensive Trademark Search Offering for Pharmaceutical Brand Owners
11. ISTA Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):